For immediate release |
17 August 2015 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Interim Results
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2015 on Wednesday 9 September 2015.
A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive |
|
|
|
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.